Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...

Adrenergic Receptors: ɑ Subtype

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...

Intracellular Signaling Affects Focal Adhesions

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...

Antihypertensive Drugs: Action of β1 Blockers

Antihypertensive Drugs: Action of β₁ Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Life-course trajectories of cardiovascular disease risk factors in rural India: Andhra Pradesh Children and Parents Study (APCAPS) 2003-2023.

International journal of epidemiology·2026

Same author

Growing CAPITOL (Critical Age Periods Impacting the Trajectory of Obesogenic Lifestyles) 4 Life.

Journal of multidisciplinary healthcare·2025

Same author

Correction: Ferdowsi et al. Capsaicin and Zinc Signalling Pathways as Promising Targets for Managing Insulin Resistance and Type 2 Diabetes. <i>Molecules</i> 2023, <i>28</i>, 2861.

Molecules (Basel, Switzerland)·2025

Same author

Body Composition Changes and Associations in Infants and Mothers During the First Year: Insights from a Pilot Study of the Baby-bod Project.

Children (Basel, Switzerland)·2025

Same author

Anthropometric prediction models of body composition in 3 to 24month old infants: a multicenter international study.

European journal of clinical nutrition·2024

Same author

Postpartum versus postnatal period: Do the name and duration matter?

PloS one·2024

Search research articles

Related Experiment Video

Updated: May 15, 2026

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

Anti-β2GP1 antibodies have variable effects on platelet aggregation.

Natasha A Betts¹, Kiran D K Ahuja, Murray J Adams

¹School of Human Life Sciences, University of Tasmania, Launceston, Tasmania, Australia.

|January 2, 2013

Summary

Rabbit anti-beta2 glycoprotein 1 (anti-β2GP1) inhibited adenosine diphosphate (ADP)-induced platelet aggregation, while human anti-β2GP1 from systemic lupus erythematosus (SLE) patients enhanced it. This highlights species-specific effects of anti-β2GP1 on platelet function.

More Related Videos

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Related Experiment Videos

Last Updated: May 15, 2026

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Area of Science:

Immunology
Hematology
Rheumatology

Background:

Antiphospholipid antibodies, including anti-beta2 glycoprotein 1 (anti-β2GP1), are associated with thrombosis in systemic lupus erythematosus (SLE).
The precise role of anti-β2GP1 in platelet activation and aggregation remains incompletely understood.
Understanding these interactions is crucial for managing thrombotic risks in SLE patients.

Purpose of the Study:

To investigate the differential effects of affinity-purified rabbit anti-β2GP1 and human anti-β2GP1 from SLE patients on adenosine diphosphate (ADP)-induced platelet aggregation.
To compare the impact of species-derived anti-β2GP1 on key parameters of platelet aggregation.

Main Methods:

Platelet-poor plasma (PPP) was obtained from 15 healthy controls and 15 SLE patients.
Anti-β2GP1 titers were measured by ELISA, and IgG fractions were isolated.
Light transmission aggregometry was used to assess the effects of rabbit and human anti-β2GP1 on ADP-induced platelet aggregation.

Main Results:

Rabbit anti-β2GP1 significantly inhibited all measured parameters of ADP-induced platelet aggregation (%Max, %AUC, slope).
In contrast, human anti-β2GP1 from SLE patients significantly enhanced %Max and %AUC in a concentration-dependent manner, while inhibiting the slope.
These contrasting effects were observed with 5 μM ADP-induced aggregation.

Conclusions:

Anti-β2GP1 purified from different species exhibit variable effects on in vitro platelet aggregation.
The observed disparities may stem from the heterogeneous nature of anti-β2GP1, differences in avidity, or distinct antibody binding specificities between rabbit and human antibodies.
These findings underscore the complexity of anti-β2GP1's role in platelet function and thrombosis.